Synergistic PDE3A Modulator and Interferon Combinations for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies often face challenges with drug resistance and low efficacy, particularly in cancers with low expression of phosphodiesterase 3A (PDE3A), necessitating the development of novel strategies to enhance treatment outcomes.
Innovation Solution
The use of synergistic combinations of phosphodiesterase 3A modulators with specific protein inhibitors, such as Bcl-2 family protein inhibitors, mTOR inhibitors, HDAC inhibitors, and others, to target cancer cells effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PDE3A specific anticancer therapy is used, then anticancer efficacy is improved in PDE3A expressing cancers, but efficacy is reduced in cancers with low PDE3A expression
Solution Approach 1:
The patent combines PDE3A modulators with interferons (IFN-α or IFN-γ) to create a synergistic therapeutic approach. This combination allows the treatment to effectively target cancer cells both through the PDE3A-SLFN12 pathway (in PDE3A expressing cancers) and through interferon-mediated SLFN12 upregulation (in cancers with low PDE3A expression), thereby resolving the contradiction between efficacy in high PDE3A cancers and adaptability to low PDE3A cancers.
Solution Approach 2:
The patent changes the therapeutic parameter by introducing interferon co-administration, which fundamentally alters the mechanism of action in low PDE3A expressing cancers. The interferon induces SLFN12 expression independently of PDE3A levels, thereby changing the efficacy parameter from PDE3A-dependent to PDE3A-independent in certain cancer contexts, expanding the versatility of the treatment.
2Reliability
If combination therapies are used, then synergistic effects and treatment outcomes are improved, but treatment complexity increases
Solution Approach 1:
The patent creates a universal treatment approach where the combination of PDE3A modulator and interferon serves multiple functions: it targets the PDE3A-SLFN12 pathway in high PDE3A cancers, upregulates SLFN12 in low PDE3A cancers, and provides synergistic anticancer effects across different cancer types. This multi-functionality improves treatment outcomes while maintaining a relatively standardized regimen that can be applied broadly.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These combinations demonstrate enhanced anticancer efficacy by inducing synergistic effects that overcome drug resistance and improve treatment outcomes in PDE3A-positive cancers.
Implementation Method 1
Binding of these molecules to PDE3A induces interaction between PDE3A and Schlafen 12 (SLFN12) protein, leading to suppression of cell growth or to cell death.
Implementation Method 2
The interaction of SLFN12 with PDE3A stabilizes SLFN12, which has normally fast turn-over within cells, and leads to elevated binding of SLFN12 to ribosomes and blocking of protein translation of anti-apoptotic proteins BCL2 and MCL1.
Implementation Method 3
IFN-α and IFN-γ induce SLFN12 expression in cells and therefore they enable Anagrelide induced cell death through the PDE3A-SLFN12 complex in PDE3A expressing cells.
Implementation Method 4
the SLFN12 interaction with PDE3A increases RNase activity of SLFN12 that is required for DNMDP response in cells.
Data Source
AI summary
The present invention is related to a composition comprising a phosphodiesterase 3A modulator compound in synergistic combination with an inhibitor compound selected from the group consisting of: an inhibitor of Bcl-2 family proteins, a mTOR inhibitor, a histone deacetylase (HDAC) inhibitor, a DNA-dependent protein kinase (DNA-PK) inhibitor, an inhibitor of integrin alpha 2 protein, a NEDD8-activating enzyme (NAE) inhibitor and a PAK4 inhibitor for use in the treatment of cancer.